Published in World J Gastroenterol on May 07, 2008
Probiotic treatment of irritable bowel syndrome in children. Ger Med Sci (2010) 0.97
Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol (2015) 0.97
State-of-the-art of irritable bowel syndrome and inflammatory bowel disease research in 2008. World J Gastroenterol (2008) 0.94
Melatonin for the treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.84
Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity. Brain Res (2010) 0.83
Molecular and functional diversity of GABA-A receptors in the enteric nervous system of the mouse colon. J Neurosci (2014) 0.81
An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. Gastroenterol Hepatol (N Y) (2010) 0.77
Irritable bowel syndrome: are complementary and alternative medicine treatments useful? Can Fam Physician (2009) 0.77
Aminophylline suppresses stress-induced visceral hypersensitivity and defecation in irritable bowel syndrome. Sci Rep (2017) 0.75
Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet (2000) 10.36
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
AGA technical review on irritable bowel syndrome. Gastroenterology (2002) 6.76
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 5.75
Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol (2000) 5.72
Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology (2002) 5.50
Lotronex and the FDA: a fatal erosion of integrity. Lancet (2001) 5.25
Bowel patterns among subjects not seeking health care. Use of a questionnaire to identify a population with bowel dysfunction. Gastroenterology (1982) 4.46
Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology (2004) 4.04
Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol (2003) 3.84
The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology (2003) 3.59
Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut (2000) 3.26
The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology (2000) 3.25
A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med (2001) 3.05
Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol (2002) 3.04
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut (2006) 2.82
The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med (1995) 2.73
Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol (2004) 2.71
Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology (2002) 2.52
Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther (2004) 2.48
A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol (2001) 2.38
A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol (2004) 2.37
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol (2004) 2.33
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther (1999) 2.28
The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm (2004) 2.25
Meta-analysis: The treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2004) 2.23
Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology (2001) 2.22
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol (2006) 2.14
Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med (2000) 2.08
Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther (2007) 2.08
Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther (2001) 2.04
A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2002) 2.03
Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol (2000) 2.00
Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol (1998) 1.96
What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut (1984) 1.96
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology (1988) 1.87
The lactulose breath hydrogen test and small intestinal bacterial overgrowth. Am J Gastroenterol (1996) 1.87
The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med (1992) 1.85
Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis (2000) 1.83
Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev (2004) 1.81
5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology (1998) 1.78
Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther (1997) 1.74
The economic consequences of irritable bowel syndrome: a US employer perspective. Arch Intern Med (2003) 1.74
Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther (1999) 1.66
Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut (2001) 1.62
Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. Gastroenterology (1990) 1.62
Adrenergic modulation of human colonic motor and sensory function. Am J Physiol (1997) 1.59
Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut (2004) 1.58
Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut (2004) 1.55
Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol (2001) 1.51
Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol (2006) 1.48
Diagnosing and treating patients with refractory functional gastrointestinal disorders. Ann Intern Med (1995) 1.47
Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg (2007) 1.46
Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology (2000) 1.45
Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. J Gastroenterol Hepatol (2007) 1.44
Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am (2005) 1.44
Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol (2004) 1.43
Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci (1984) 1.41
Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2004) 1.41
Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil (2003) 1.39
Ramosetron, a 5-HT3 receptor antagonist for the control of nausea and vomiting. Drugs Today (Barc) (2002) 1.38
Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol (1998) 1.37
Role of CRF in stress-related alterations of gastric and colonic motor function. Ann N Y Acad Sci (1993) 1.33
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther (1998) 1.33
Peripheral 5-HT4 receptors. FASEB J (1996) 1.32
Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology (1991) 1.29
What patients know about irritable bowel syndrome (IBS) and what they would like to know. National Survey on Patient Educational Needs in IBS and development and validation of the Patient Educational Needs Questionnaire (PEQ). Am J Gastroenterol (2007) 1.29
Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol (2001) 1.28
Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J Gastroenterol (2007) 1.26
Role of corticotropin-releasing hormone in irritable bowel syndrome and intestinal inflammation. J Gastroenterol (2007) 1.24
Effects of a serotonin 5-HT(4) receptor antagonist SB-207266 on gastrointestinal motor and sensory function in humans. Gut (2000) 1.23
Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. Dig Dis Sci (1987) 1.23
Clinical perspectives, mechanisms, diagnosis and management of irritable bowel syndrome. Aliment Pharmacol Ther (2002) 1.20
Effect of mosapride on gastrointestinal transit time and diagnostic yield of capsule endoscopy. J Gastroenterol Hepatol (2007) 1.19
A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS. Am J Gastroenterol (2007) 1.17
Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil (2007) 1.17
Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol (2004) 1.16
Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med (1999) 1.15
5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut (1994) 1.15
Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol (1998) 1.14
A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther (2000) 1.13
Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci (1994) 1.13
Effects of a kappa-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans. Am J Physiol Gastrointest Liver Physiol (2003) 1.13
Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther (1994) 1.11
Effect of asimadoline, a kappa opioid agonist, on pain induced by colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther (2004) 1.10
Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther (1997) 1.09
Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol (2006) 1.09
Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study. Am J Gastroenterol (2005) 1.09
Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol (2005) 1.08
Ramosetron versus ondansetron in the prevention of chemotherapy-induced gastrointestinal side effects: A prospective randomized controlled study. Chemotherapy (2007) 1.07
A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol (2003) 1.07
Psychologic considerations in the irritable bowel syndrome. Gastroenterol Clin North Am (1991) 1.07
Use of psychopharmacological agents for functional gastrointestinal disorders. Gut (2005) 1.06
Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. Aliment Pharmacol Ther (2007) 1.05
The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther (2002) 1.05
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol (2002) 3.24
Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol (2010) 1.59
The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol (2012) 1.40
Safety and acceptability of the Reality condom for anal sex among men who have sex with men. AIDS (2003) 1.28
Probiotics in the prevention and treatment of gastrointestinal infections. Gastroenterol Clin North Am (2006) 1.06
Clostridium difficile infection in the elderly. Clin Geriatr Med (2014) 1.05
Clostridium difficile infection. Lancet (2008) 1.01
Emerging infections of the gastrointestinal tract. Best Pract Res Clin Gastroenterol (2009) 1.00
Clinical correlation of toxin and common antigen enzyme immunoassay testing in patients with Clostridium difficile disease. Am J Gastroenterol (2003) 0.95
Clostridium difficile Infection. Med Clin North Am (2013) 0.90
Alteration of the intestinal microbiome: fecal microbiota transplant and probiotics for Clostridium difficile and beyond. Expert Rev Gastroenterol Hepatol (2013) 0.85
Treatment strategies for C. difficile associated diarrhea. Acta Gastroenterol Latinoam (2007) 0.85
Infectious diarrhea: an overview. Curr Gastroenterol Rep (2014) 0.83
Evolving concepts in Clostridium difficile colitis. Curr Gastroenterol Rep (2009) 0.83
Reining in recurrent Clostridium difficile infection--who's at risk? Gastroenterology (2009) 0.82
Infectious causes of chronic diarrhoea. Best Pract Res Clin Gastroenterol (2012) 0.81
Gastro 2013 APDW/WCOG Shanghai working party report: chronic diarrhea: definition, classification, diagnosis. J Gastroenterol Hepatol (2014) 0.81
Chronic diarrhea. Clin Gastroenterol Hepatol (2005) 0.80
Antibiotic-associated diarrhea in children: how many dirty diapers? J Pediatr Gastroenterol Nutr (2003) 0.80
Antibiotics and Clostridium difficile: cause and cure. J Clin Gastroenterol (2007) 0.78
The gut microbiome: a clinically significant player in transplantation? Expert Rev Clin Immunol (2015) 0.78
Current Treatment Options for Severe Clostridium difficile-associated Disease. Gastroenterol Hepatol (N Y) (2008) 0.77
The gut microbiota: a microbial arsenal protecting us from infectious and radiation-induced diarrhea. Gastroenterology (2008) 0.77
The changing face of Clostridium difficile: what treatment options remain? Am J Gastroenterol (2007) 0.76
Loperamide use for acute infectious diarrhea in children: safe and sound? Gastroenterology (2008) 0.76
Do we need our gastric acid? Risk of bacterial gastroenteritis with proton pump inhibitors. Gastroenterology (2008) 0.75
Editorial: Clostridium difficile infection: Yet another predictor of poor outcome in cirrhosis. Am J Gastroenterol (2010) 0.75
The acid test: is proton pump inhibitor therapy an independent risk factor for Clostridium difficile-associated disease? Gastroenterology (2007) 0.75
Irritable bowel syndrome: a chronic sequelae of acute gastroenteritis. Gastroenterology (2007) 0.75
Infection: treating recurrent C. difficile infection-the challenge continues. Nat Rev Gastroenterol Hepatol (2012) 0.75
Shigella: a sexually transmitted infection in men who have sex with men. Gastroenterology (2007) 0.75
Cytomegalovirus in inflammatory bowel disease: time for another look? Gastroenterology (2009) 0.75
Emergency colectomy in severe Clostridium difficile-associated disease: the sooner the better for some. Gastroenterology (2007) 0.75
C difficile--C'est Difficile? Gastroenterology (2006) 0.75
Fecal microbiota transplantation: what we know and what we need to know. Ann Intern Med (2015) 0.75
Probiotics and prebiotics in clinical practice. Nutr Clin Care (2004) 0.75
Diagnosis of celiac disease in a patient with fecal incontinence. Nat Clin Pract Gastroenterol Hepatol (2006) 0.75
Treatment strategies for recurrent and refractory Clostridium difficile-associated diarrhea. Expert Rev Gastroenterol Hepatol (2007) 0.75
Maintenance infliximab infusions forever? Am J Gastroenterol (2002) 0.75